Noveome Biotherapeutics, Inc. To Present At The 2019 Flagship Ophthalmology Innovation Summit
PITTSBURGH, PA – October 3, 2019 – Noveome Biotherapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing next-generation biologics for the promotion and restoration of cellular integrity of inflamed or damaged tissues, today announced David Steed, M.D., Executive VP of Medical Affairs, Chief Medical Officer of Noveome Biotherapeutics, will present details on its optic nerve disease clinical program at the 2019 Flagship Ophthalmology Innovation Summit (OIS) on Thursday, October 10, 2019 at 11:44 am P.T. in San Francisco, CA. Dr. Steed’s presentation will follow an introduction by long time Ophthalmology Commercial Executive, Patrick Welch, MBA, who was previously VP of Sales and Marketing for the U.S. Retina Business Unit at Allergan.
About The Optic Nerve Disease Clinical Program
ST266 has been shown to protect and resuscitate neural and retinal ganglion cells in preclinical models of optic neuritis and optic nerve crush. Noveome is employing an innovative, non-invasive, targeted intranasal device to deliver ST266 directly to the optic nerve. This route of administration by-passes the blood-brain barrier, historically a major hurdle to the successful delivery of medicines to the central nervous system. Noveome is currently conducting a Phase 1 open label clinical trial to establish the safety of ST266 when delivered by this intranasal route. Topline data are expected in 2019.
About Noveome Biotherapeutics, Inc.
Noveome Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing next- generation biologics for the promotion and restoration of cellular integrity of inflamed or damaged tissues. Noveome’s multi-target platform biologic and lead product, ST266, is currently being evaluated in multiple indications across ophthalmic, CNS, pulmonary, and gastrointestinal therapeutic areas. In addition to the Phase 1 open label clinical trial to establish the safety of ST266 when delivered intranasally, Noveome is currently conducting a Phase 2 open-label clinical trial evaluating the efficacy of ST266 in healing PEDs when delivered topically to the eye. Topline data for thistrial are expected in 2019. Preclinical resultstesting ST266 in chronic traumatic encephalopathy (CTE), emphysema, polytrauma, and necrotizing enterocolitis (NEC) are also expected later in 2019. The Company received seed funding from Lancet Capital, a venture capital consortium of leading Pittsburgh healthcare institutions including UPMC Enterprises, Highmark Blue Cross/Blue Shield, University of Pittsburgh and Carnegie Mellon University. To date, Noveome has received over $120 million in research and infrastructure funding from the U.S. Department of Defense, the Commonwealth of Pennsylvania and Allegheny County. Noveome is based in Pittsburgh, PA. For more information, please visit, www.noveome.com.
Investor Contact:
Julie Seidel
Stern Investor Relations, Inc.
212-362-1200
julie.seidel@sternir.com